Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to $652000.0.

  • Mereo BioPharma's Other Non-Current Liabilities fell 3730.77% to $652000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $652000.0, marking a year-over-year decrease of 3730.77%. This contributed to the annual value of $821000.0 for FY2024, which is 746.07% up from last year.
  • Mereo BioPharma's Other Non-Current Liabilities amounted to $652000.0 in Q3 2025, which was down 3730.77% from $545000.0 recorded in Q2 2025.
  • Mereo BioPharma's Other Non-Current Liabilities' 5-year high stood at $47.5 million during Q2 2021, with a 5-year trough of $419000.0 in Q1 2025.
  • Its 5-year average for Other Non-Current Liabilities is $6.2 million, with a median of $862000.0 in 2022.
  • As far as peak fluctuations go, Mereo BioPharma's Other Non-Current Liabilities crashed by 9226.66% in 2022, and later skyrocketed by 746.07% in 2024.
  • Mereo BioPharma's Other Non-Current Liabilities (Quarter) stood at $11.2 million in 2021, then tumbled by 92.27% to $869000.0 in 2022, then decreased by 12.08% to $764000.0 in 2023, then rose by 7.46% to $821000.0 in 2024, then decreased by 20.58% to $652000.0 in 2025.
  • Its last three reported values are $652000.0 in Q3 2025, $545000.0 for Q2 2025, and $419000.0 during Q1 2025.